Loading organizations...
Loading organizations...
Remedee Labs is a technology company.
Remedee Labs develops innovative, non-invasive millimeter wave neuromodulation technology integrated into a wearable device. This personal stimulator targets specific biological pathways to encourage the body's natural production of endorphins, offering an alternative approach to managing chronic pain. The company's technology represents a distinct method for physiological intervention, utilizing precise energy delivery to provide therapeutic benefits without pharmacological dependencies.
The company was founded in 2016 by David Crouzier, Michael Foerster, and Jacques. Their collective insight centered on the potential of millimeter wave technology to activate the body’s endogenous pain relief systems, leading to the development of their novel solution. This approach emerged from a deep understanding of neurophysiology and a desire to address chronic pain challenges with a non-pharmacological method.
Remedee Labs’ product is designed for individuals seeking effective and accessible alternatives for chronic pain management. The company’s long-term vision is to establish a new standard of care by empowering patients with a drug-free option, thereby improving their daily lives and overall well-being. Their mission is to redefine pain management through accessible and natural physiological mechanisms.
Remedee Labs has raised $25.0M across 2 funding rounds.
Remedee Labs has raised $25.0M in total across 2 funding rounds.
Remedee Labs has raised $25.0M in total across 2 funding rounds.
Remedee Labs's investors include Hardware Club, Alexis Houssou, C4 Ventures, Habert Dassault Finance, Partech, Supernova Invest.
Remedee Labs is a French health tech company founded in 2016 that develops wearable endorphin stimulators using millimeter-wave neuromodulation to provide drug-free relief for chronic pain sufferers.[1][2][3] Its core product is a wristband device, such as the medical-grade solution for fibromyalgia (authorized in Europe in 2024) and the non-medical Remedee Well for general well-being, paired with a patient-centric digital platform offering personalized multidisciplinary support, including remote coaching and behavioral programs.[1][3][5] Targeting the 1.5 billion people worldwide with chronic pain—where over half are dissatisfied with care—the company addresses unmet needs in conditions like fibromyalgia, osteoarthritis, and rheumatic pain, with clinical validation showing significant improvements in pain, sleep, and quality of life for 8/10 users.[2][5][6] Backed by $24.8 million in funding from investors like Generali France and Hardware Club, Remedee Labs is gearing up for medical commercialization in early 2025.[1][2]
Remedee Labs was founded in 2016 in Montbonnot-Saint-Martin, France, by co-founders Jacques Husser (Executive Chairman, former COO at SIGFOX), David Crouzier (CEO, former Head of Risk Emerging Technologies Lab at Service de Santé des Armées), and Michael Foerster (CTO, former CTO at Nivolog).[2][3][4] The trio, experts in micro/nano medical technologies, biomedical research, and silicon breakthroughs, revived 1970s millimeter-wave therapy—once limited to bulky hospital equipment—by miniaturizing it into a wearable via their patented Microelectronic Endorphin Trigger (MEET) module.[1][4] Key early milestones include winning the BPI National iLab competition in 2017, filing patents in 2018 (now 9-12 internationally, including with CEA), and collaborating with CEA-Leti and pain centers for clinical studies proving efficacy in rheumatic pain.[1][3] Pivotal traction came from European hospital trials and 2024 fibromyalgia authorization, humanizing their mission to break the chronic pain cycle affecting sleep, stress, mobility, and daily life.[3][5]
Remedee Labs rides the neuromodulation and digital therapeutics wave, merging wearables, AI-driven personalization, and non-opioid pain management amid a global chronic pain epidemic (1.5B affected) and backlash against pharmaceuticals post-opioid crisis.[2][5][7] Timing aligns with regulatory wins like its 2024 fibromyalgia CE mark—the first for such tech in Europe—and post-pandemic demand for at-home, telehealth-enabled solutions, especially as 70% of French patients lack proper care.[1][6] Favorable market forces include aging populations, rising osteoarthritis/fibromyalgia prevalence, and investor interest in hardware-health hybrids (e.g., $24.8M raised).[2] It influences the ecosystem by validating millimeter-wave revival via CEA collaborations, paving the way for miniaturized medtech wearables and patient-centered platforms that reduce hospital dependency.[1][4]
With medical launch slated for early 2025, Remedee Labs is poised for scale via its fibromyalgia flagship, expanding to osteoarthritis and beyond, leveraging clinical data and platform stickiness for recurring revenue.[1][5] Trends like AI-enhanced personalization, non-drug pain tech mandates (e.g., vs. opioids), and global wearables growth will propel it, potentially capturing share in a $100B+ chronic pain market. Influence may evolve from niche innovator to ecosystem leader through partnerships and new indications, redefining at-home neuromodulation—ultimately delivering drug-free relief to millions, as promised since its 2016 inception.[3][5]
Remedee Labs has raised $25.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $13.0M Series A | Hardware Club | |
| Nov 1, 2019 | $12.0M Series A | Alexis Houssou | Hardware Club, C4 Ventures, Habert Dassault Finance, Partech, Supernova Invest |